• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三文鱼下肠道对蛋白质和肽类药物口服给药的代谢屏障。

The metabolic barrier of the lower intestinal tract of salmon to the oral delivery of protein and peptide drugs.

作者信息

Ledger R, Tucker I G, Walker G F

机构信息

School of Pharmacy, University of Otago, PO Box 913, Dunedin, New Zealand.

出版信息

J Control Release. 2002 Dec 13;85(1-3):91-103. doi: 10.1016/s0168-3659(02)00289-4.

DOI:10.1016/s0168-3659(02)00289-4
PMID:12480315
Abstract

Oral delivery of peptide and protein drugs has potential advantages for the aquaculture industry. The bioavailability of proteins and peptides from the intestinal tract is very low. This can be attributed in part to the proteolytic activities of the intestine. Bovine serum albumin (BSA), human (hLHRH) and salmon (sLHRH) luteinizing-hormone releasing hormones were used to evaluate the proteolytic activity of anterior, middle and posterior sections of the Quinnat salmon (Oncorhynchus tshawytscha) intestinal tract. The lumenal proteolytic activities of the posterior intestinal section towards BSA were approximately half that of the anterior and middle sections. The half-lives of the LHRH analogues in the posterior were twofold longer than for the anterior and middle sections. Proteolytic activity of the posterior mucosal homogenates towards BSA was fourfold higher than the middle mucosal homogenates. LHRH analogues were hydrolysed by the posterior mucosal homogenate, whereas in the middle mucosal homogenate they were stable. Soybean trypsin inhibitor was shown to be the most effective inhibitor of lumenal proteolytic activity towards LHRH analogues. Sodium deoxycholate, EDTA and bestatin significantly inhibited the posterior mucosal hydrolytic activity towards the LHRH analogues. The posterior intestine of salmon is the most favourable site for the delivery of BSA and LHRH analogues with respect to the lumen, however the higher proteolytic activity of the posterior mucosa has to be overcome.

摘要

肽和蛋白质药物的口服给药对水产养殖业具有潜在优势。肠道中蛋白质和肽的生物利用度非常低。这部分可归因于肠道的蛋白水解活性。使用牛血清白蛋白(BSA)、人(hLHRH)和鲑鱼(sLHRH)促黄体激素释放激素来评估奇努克鲑(Oncorhynchus tshawytscha)肠道前段、中段和后段的蛋白水解活性。肠道后段对BSA的腔内蛋白水解活性约为前段和中段的一半。促黄体激素释放激素类似物在后段的半衰期比前段和中段长两倍。后段黏膜匀浆对BSA的蛋白水解活性比中段黏膜匀浆高四倍。促黄体激素释放激素类似物在后段黏膜匀浆中被水解,而在中段黏膜匀浆中它们是稳定的。大豆胰蛋白酶抑制剂被证明是对促黄体激素释放激素类似物腔内蛋白水解活性最有效的抑制剂。脱氧胆酸钠、乙二胺四乙酸(EDTA)和贝抑素显著抑制后段黏膜对促黄体激素释放激素类似物的水解活性。就肠腔而言,鲑鱼的后段肠道是递送BSA和促黄体激素释放激素类似物的最有利部位,然而必须克服后段黏膜较高的蛋白水解活性。

相似文献

1
The metabolic barrier of the lower intestinal tract of salmon to the oral delivery of protein and peptide drugs.三文鱼下肠道对蛋白质和肽类药物口服给药的代谢屏障。
J Control Release. 2002 Dec 13;85(1-3):91-103. doi: 10.1016/s0168-3659(02)00289-4.
2
Activity of pancreatic endopeptidases towards luteinizing hormone-releasing hormones.胰腺内肽酶对促黄体生成激素释放激素的活性。
Int J Pharm. 2001 Mar 23;216(1-2):77-82. doi: 10.1016/s0378-5173(01)00571-3.
3
Enzymatic degradation of luteinizing hormone releasing hormone (LHRH) by mucosal homogenates from the intestine of the common brushtail possum (Trichosurus vulpecula).
Life Sci. 2002 Nov 8;71(25):3019-30. doi: 10.1016/s0024-3205(02)02163-x.
4
Inhibition of proteolysis in luminal extracts from the intestine of the brushtail possum.抑制帚尾袋貂肠道腔提取物中的蛋白水解作用。
J Pharm Pharmacol. 2002 Oct;54(10):1365-72. doi: 10.1211/002235702760345446.
5
[Improvement of intestinal absorption of peptide and protein drugs by chemical modification with fatty acids].[通过脂肪酸化学修饰改善肽类和蛋白质药物的肠道吸收]
Nihon Rinsho. 1998 Mar;56(3):601-7.
6
Protein and peptide degradation in the intestine of the common brushtail possum (Trichosurus vulpecula).帚尾袋貂(Trichosurus vulpecula)肠道中的蛋白质和肽降解
J Comp Physiol B. 2002 Oct;172(7):553-9. doi: 10.1007/s00360-002-0281-0. Epub 2002 Jul 25.
7
[Methodologies for regulation of intestinal absorption of biologically active peptides].[调节生物活性肽肠道吸收的方法]
Nihon Rinsho. 1998 Mar;56(3):589-94.
8
[Improvement of transmucosal absorption of biologically active peptide drugs].[生物活性肽类药物经黏膜吸收的改善]
Yakugaku Zasshi. 2001 Dec;121(12):929-48. doi: 10.1248/yakushi.121.929.
9
The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins.使用抑制剂来克服口服治疗性肽和蛋白质的酶屏障。
J Control Release. 1998 Mar 2;52(1-2):1-16. doi: 10.1016/s0168-3659(97)00204-6.
10
[Improvement of Intestinal and Transmucosal Absorption of Peptide and Protein Drugs].[肽类和蛋白质药物肠道及跨黏膜吸收的改善]
Yakugaku Zasshi. 2024;144(7):697-714. doi: 10.1248/yakushi.23-00199.